These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24935295)

  • 21. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Sirolimus use in heart transplantation recipients with chronic renal dysfunction].
    Yin D; Huang J; Feng L; Liao ZK; Feng GX; Wang W; Song YH; Hu SS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb; 40(2):136-40. PubMed ID: 22490714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcineurin inhibitor conversion to rapamycin can improve graft function in living donor kidney transplantation with older donors.
    Chen GD; Liu XC; Shi L; Qiu J; Wang CX; Fei JG; Li J; Huang G; Chen LZ
    Transplant Proc; 2013 May; 45(4):1648-50. PubMed ID: 23726640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S; Gurkan A; Karaca C; Varılsuha C; Tilif S
    Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk in kidney transplant recipients receiving mammalian target of rapamycin inhibitors.
    Watorek E; Szymczak M; Boratynska M; Patrzalek D; Klinger M
    Transplant Proc; 2011 Oct; 43(8):2967-9. PubMed ID: 21996202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR; Augustine JJ; Krishnamurthi V; Goldfarb DA; Flechner SM; Braun WE; Hricik DE; Dennis VW; Poggio ED
    Transplantation; 2006 Aug; 82(3):368-74. PubMed ID: 16906035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients.
    Balfour IC; Srun SW; Wood EG; Belsha CW; Marshall DL; Ferdman BR
    J Heart Lung Transplant; 2006 May; 25(5):518-22. PubMed ID: 16678029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
    Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First experience with rapamycin-based immunosuppression to improve kidney function after heart transplantation.
    Trösch F; Rothenburger M; Schneider M; Welp H; Etz C; Wilhelm MJ; Scheld HH; Schmid C
    Thorac Cardiovasc Surg; 2004 Jun; 52(3):163-8. PubMed ID: 15192777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.
    Rothenburger M; Teerling E; Bruch C; Lehmkuhl H; Suwelack B; Bara C; Wichter T; Hinder F; Schmid C; Stypmann J
    J Heart Lung Transplant; 2007 Mar; 26(3):250-7. PubMed ID: 17346627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients.
    Chinnock TJ; Shankel T; Deming D; Cutler D; Sahney S; Fitts J; Chinnock RE
    Pediatr Transplant; 2011 Nov; 15(7):746-9. PubMed ID: 21883751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sirolimus experience in heart transplantation.
    Aranda-Dios A; Lage E; Sobrino JM; Mogollón MV; Guisado A; Cabezón S; Hinojosa R; Hernández A; Ordóñez A
    Transplant Proc; 2006 Oct; 38(8):2547-9. PubMed ID: 17097997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.
    Haidinger M; Hecking M; Weichhart T; Poglitsch M; Enkner W; Vonbank K; Prayer D; Geusau A; Oberbauer R; Zlabinger GJ; Soleiman A; Hörl WH; Säemann MD
    Transpl Int; 2010 Aug; 23(8):777-85. PubMed ID: 20070623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.